Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.53 |
| ▸ | THRA | P10827 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 6/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578977 | 0.96 | THRA (0.55) | RARBTHRATHRBALDH1A1FFAR1 | |
| SCHEMBL762946 | 0.92 | ACACB (0.50) | THRBPLK1ALDH1A1FFAR1FFAR4 | |
| SCHEMBL28645496 | 0.91 | RARB (0.62) | RARBTHRATHRBPLK1ALDH1A1 | |
| SCHEMBL2356098 | 0.84 | THRA (0.67) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL5547984 | 0.84 | THRA (0.67) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL10651489 | 0.84 | THRA (0.67) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL2722720 | 0.84 | THRA (0.67) | RARBTHRATHRBALDH1A1HAO1 | |
| SCHEMBL1811178 | 0.84 | RARB (0.73) | RARBTHRATHRBPLK1ALDH1A1 | |
| SCHEMBL2402922 | 0.83 | RARB (0.71) | RARBTHRATHRBPLK1ALDH1A1 | |
| SCHEMBL9418034 | 0.81 | HSD17B10 (0.56) | RARBTHRATHRBPLK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8139189-B2 | Liquid crystal display having particular oblique vapor deposition-alignment layer with ferroelectric liquid crystal | DAI NIPPON PRINTING CO., LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20120056129-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8130358-B2 | Liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8009266-B2 | Process for producing liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7871540-B2 | Polymerizable liquid crystal composition | DIC CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100060844-A1 | PROCESS FOR PRODUCING LIQUID CRYSTAL DISPLAY | DAI NIPPON PRINTING CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100053525-A1 | LIQUID CRYSTAL DISPLAY | DAI NIPPON PRINTING CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100007832-A1 | LIQUID CRYSTAL DISPLAY | DAI NIPPON PRINTING CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2093610-A1 | PROCESS FOR PRODUCING LIQUID CRYSTAL DISPLAY ELEMENT | Dai Nippon Printing Co., Ltd. (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-7570331-B2 | Liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7499135-B2 | Liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20090050844-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090050844-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION | H1-0, H1-4, H1-10 | RARB 3123/4885THRA 2549/4885THRB 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.